Recro Pharma Inc (REPH) was Resumed by Brean Capital to “Buy”. Brean Capital advised their investors in a research report released on Oct 3, 2016.
Many Wall Street Analysts have commented on Recro Pharma Inc. Recro Pharma Inc was Initiated by ROTH Capital to “Buy” on Sep 16, 2016.
Recro Pharma Inc closed down -0.08 points or -0.90% at $8.84 with 35,349 shares getting traded on Friday. Post opening the session at $8.94, the shares hit an intraday low of $8.5224 and an intraday high of $8.94 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jun 2, 2016, Fred Graff (Chief Commercial Officer) purchased 8,000 shares at $8.46 per share price. According to the SEC, on May 31, 2016, Stewart Mccallum (Chief Medical Officer) purchased 1,250 shares at $8.32 per share price. On May 25, 2016, Randall Mack (Senior VP, Development) purchased 2,000 shares at $6.30 per share price, according to the Form-4 filing with the securities and exchange commission.
Recro Pharma Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN Dex-SL and Fadolmidine (Fado). Dex-IN is a product candidate under development for the treatment of post-operative pain and for the treatment of cancer breakthrough pain. Dex-SL is a product candidate for the treatment of chronic pain. Fado is a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies) especially of the lower extremities which can occur in diabetic patients.